BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Arcturus Bioscience, Inc. Presents Results From Two Gene Prognostic Biomarker Studies At 28th Annual San Antonio Breast Cancer Symposium


12/6/2005 11:22:55 AM

CARLSBAD, Calif., Dec. 6 /PRNewswire/ -- Arcturus Bioscience will present results from two internal clinical studies validating the company's proprietary two gene index, HOXB13:IL-17BR (H:I Index), as a potential prognostic biomarker for the assessment of disease recurrence risk in breast cancer patients at the 28th Annual San Antonio Breast Cancer Symposium, taking place December 8-11, 2005.

Arcturus and Massachusetts General Hospital previously described the discovery of the H:I Index as a predictor of clinical outcome in breast cancer patients receiving hormonal therapy. At the Breast Cancer Symposium, Arcturus presents two independent studies with Mayo Clinic and the Baylor Breast Cancer Center that confirm this original finding. In the first study conducted at the Mayo Clinic, the H:I Index is shown to be significantly associated with outcome in samples from a prospective randomized trial of 206 breast cancer patients receiving hormonal therapy. In the second study, with the Baylor Breast Cancer Center, the H:I Index was analyzed in a retrospective set of 852 patients. Results from this study further demonstrate the clinical utility of the H:I Index as a prognostic factor in breast cancer patients.

Results from both studies will be presented at the Posters/Discussion Session entitled "Expression Profiles in Prognosis and Prediction."

Poster Title: A two-gene expression ratio of HOXB13 and IL-17BR for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Presenter: Matthew P. Goetz, M.D., Breast Clinic, Mayo Clinic, Rochester, MN Time: Saturday, December 10, 5:00 to 7:00 p.m. in Ballroom A Poster Title: The HOXB13:IL17BR Index as a prognostic factor for early breast cancer. Presenter: Mark G. Erlander, Ph.D., Arcturus Bioscience, San Diego, CA Time: Saturday, December 10, 5:00 to 7:00 p.m. in Ballroom A

About Arcturus Bioscience: The molecular diagnostic business unit of Arcturus Bioscience is developing clinically-relevant signatures associated with cancer. In addition to breast cancer, Arcturus has recently presented technology that enables the molecular classification of multiple cancer types.

Arcturus Bioscience

CONTACT: Antonius Schuh of Arcturus, +1-760-579-0500



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES